Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine Versus Sufentanil for Postoperative Analgesia and Gastrointestinal Tolerability After Major Laparoscopic Abdominal Surgery
NCT07637968Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2027
01
Overview
Phase 4, randomised, triple-blind trial of tegileridine in postoperative pain (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Area Under the Curve of Resting Pain Intensity. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07637968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637968.